# US 2026/0116928 A1 · Compositions and particles for payload delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0116928 A1
- Document ID: US20260116928A1
- Status: Published application
- Kind: A1
- Application number: 18/774,008
- Filed: 2024-07-16
- Published: 2026-04-30
- Earliest claimed: 2019-08-16
- Assignees: Thornhill Therapeutics, Inc.
- Applicants: Thornhill Therapeutics, Inc.
- Inventors: Randall J. MRSNY; Derek MACLEAN; Michael SEKAR; Kevin YIN; Tahir MAHMOOD; Thomas Carl HUNTER; Keyi LIU
- Web page: https://patentgrep.com/patent/US20260116928A1

## CPC

- C07K 14/195: from bacteria
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 14/54: Interleukins [IL]
- C07K 14/605: Glucagons
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 17/06: attached to the carrier via a bridging agent
- C12R 2001/385: Pseudomonas aeruginosa
- C12R 2001/63: Vibrio
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.

## Claims

### Claim at position 1

-145. (canceled)

### Claim 146

A composition comprising:
a carrier derived from a bacterial toxin capable of entering a polarized epithelial cell or transcytosing across a polarized epithelial cell; and
a transition metal cation, a divalent metal cation or a polycation, wherein the polycation is a molecule or chemical complex having more than 2 positive charges.

### Claim 147 (depends on 146)

The composition of claim 146, wherein the composition comprising the transition metal cation, and wherein the transition metal cation is selected from the group consisting of Fe2+, Mn2+, Zn2+, Co2+, Ni2+, and Cu2+.

### Claim 148 (depends on 147)

The composition of claim 147, wherein the transition metal cation comprises Zn2+.

### Claim 149 (depends on 146)

The composition of claim 146, wherein the composition comprising the divalent metal cation, and wherein the metal cation is a divalent metal cation.

### Claim 150 (depends on 149)

The composition of claim 149, wherein the divalent metal cation comprises Mg2+.

### Claim 151 (depends on 146)

The composition of claim 146, wherein the composition comprises the polycation.

### Claim 152 (depends on 146)

The composition of claim 146, further comprising a heterologous payload.

### Claim 153 (depends on 146)

The composition of claim 146, wherein the carrier comprises Pseudomonas exotoxin A or a portion of the Pseudomonas exotoxin A.

### Claim 154 (depends on 146)

The composition of claim 146, wherein the carrier comprises a Cholix polypeptide.

### Claim 155 (depends on 152)

The composition of claim 152, wherein the heterologous payload comprises an incretin.

### Claim 156 (depends on 152)

The composition of claim 152, wherein the heterologous payload comprises glucagon-like peptide 2 (GLP-2) or a GLP-2 analog.

### Claim 157 (depends on 156)

The composition of claim 156, wherein the heterologous payload comprises the GLP-2 analog, wherein the GLP-2 analog is teduglutide.

### Claim 158

A composition comprising a carrier capable of entering a polarized epithelial cell or transcytosing across a polarized epithelial cell; and a heterologous payload, wherein a molar ratio of the heterologous payload to the carrier is greater than 1:1, wherein the carrier is not covalently linked to the heterologous payload.

### Claim 159 (depends on 158)

The composition of claim 158, wherein the composition further comprises a transition metal cation or a divalent metal cation.

### Claim 160 (depends on 159)

The composition of claim 159, wherein the composition comprises the transition metal cation, and wherein the transition metal cation is selected from the group consisting of: Fe2+, Mn2+, Zn2+, Co2+, Ni2+, and Cu2+.

### Claim 161 (depends on 160)

The composition of claim 160, wherein the transition metal cation is Zn2+.

### Claim 162 (depends on 159)

The composition of claim 159, wherein the composition comprises the divalent metal cation, and wherein the divalent metal cation is Mg2+.

### Claim 163 (depends on 158)

The composition of claim 158, wherein the carrier comprises a portion of a Cholix polypepude.

### Claim 164 (depends on 158)

The composition of claim 158, wherein the heterologous payload is a glucagon-like peptide-2 (GLP-2) analog.

### Claim 165 (depends on 164)

The composition of claim 164, wherein the GLP-2 analog is Teduglutide.
